Evaxion Biotech out-licensed vaccine candidate EVX-B3 to MSDMerck

Evaxion (EVAX) has out-licensed its vaccine candidate EVX-B3 to Merck & Co. (MRK), MSD, as per the option and license agreement entered between the two companies in September 2024. Evaxion will receive a cash payment of $7.5M and will be eligible for future development, regulatory and sales milestone payments of up to $592M, as well as royalties on net sales. MSD will assume full responsibility and carry all costs for the further development of the EVX-B3 vaccine. “We are delighted that MSD has exercised its option on EVX-B3 following a very successful collaboration. This has significant financial value for us, but equally important is the massive validation of our AI-Immunology platform by MSD, the world leader in vaccine development and commercialization. We could not have found a better partner to develop and maximize the full potential for our AI-discovered vaccine candidate. Further, this exemplifies our strategic approach to monetize value through high-impact partnerships,” says Birgitte Rono, CSO and interim CEO of Evaxion.